Over the next six years, the purchase and production of biosimilar drugs can expect to see high double-digit growth. Are you familiar with the trends driving growth in the hottest market in therapeutic development?
CDISC standards are now mandatory. Your organization can either treat them as another regulatory weight, or use them to mitigate risk, drive down costs, and increase efficiency.
Biorasi is not just a contract research organization. We are Clinical Research Optimized™, which means that we achieve the ideal balance of cost, time and risk management. Through innovative project management processes and technologies, dedication to our sponsors, and a culture of ownership, our team will deliver to you on time, on budget, results every time.
MIAMI, FL – ( April 12, 2017) – Biorasi, LLC. announced today that their Vice President of Drug Safety and Pharmacovigilance, Mark Vieder, RPh, MBA, has been officially selected to join the faculty of the DIA (founded as the Drug Information Association). This...read more
Over the next five years, the purchase and production of biosimilar drugs can expect to see double-digit growth. As biosimilar drugs become more widely produced, prescribed, used, and accepted, the competitive marketplace will continue to heat up. What are the drivers...read more
The study is behind schedule. Enrollment is lagging. The protocol is too complicated. Approximately 80 percent of all clinical studies need intervention or optimization to be successful, but only about 10 percent get it. Why? Because there is an negative connotation...read more